{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:30:29Z","timestamp":1778895029328,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000723","name":"Tenovus","doi-asserted-by":"publisher","award":["T15\/59"],"award-info":[{"award-number":["T15\/59"]}],"id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["214588\/Z\/18\/Z"],"award-info":[{"award-number":["214588\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaip.2021.04.055","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T15:41:17Z","timestamp":1620315677000},"page":"3431-3439.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study"],"prefix":"10.1016","volume":"9","author":[{"given":"Daniel R.","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Donnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.jaip.2021.04.055_bib1","first-page":"iv1","article-title":"British guideline on the management of asthma","volume":"63","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2021.04.055_bib2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12971","article-title":"Comorbidities in adults with asthma: population-based cross-sectional analysis of 1.4 million adults in Scotland","volume":"47","author":"Weatherburn","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.04.055_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4104\/pcrj.2013.00107","article-title":"Chronic disease co-morbidity of asthma and unscheduled asthma care among adults: results of the national telephone health interview survey German Health Update (GEDA) 2009 and 2010","volume":"23","author":"Steppuhn","year":"2014","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.jaip.2021.04.055_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/thx.47.11.979","article-title":"Bradykinin and asthma","volume":"47","author":"Barnes","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2021.04.055_bib8","first-page":"176","article-title":"Bradykinin-induced bronchoconstriction in humans. Mode of action","volume":"135","author":"Fuller","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2021.04.055_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1367","article-title":"Comparative airway responses to inhaled bradykinin, kallidin, and [des-Arg9] bradykinin in normal and asthmatic subjects","volume":"142","author":"Polosa","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2021.04.055_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/ajrccm.153.1.8542147","article-title":"Airway responsiveness to bradykinin is related to eosinophilic inflammation in asthma","volume":"153","author":"Roisman","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.04.055_bib11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data Resource Profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaip.2021.04.055_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib13","doi-asserted-by":"crossref","first-page":"e017474","DOI":"10.1136\/bmjopen-2017-017474","article-title":"Validation of asthma recording in the Clinical Practice Research Datalink (CPRD)","volume":"7","author":"Nissen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2021.04.055_bib14","doi-asserted-by":"crossref","first-page":"e023090","DOI":"10.1136\/bmjopen-2018-023090","article-title":"Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation [published correction appears in BMJ Open. 2019 Feb 22;8(11):e023090corr1]","volume":"8","author":"Pacurariu","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2021.04.055_bib16","doi-asserted-by":"crossref","first-page":"e005540","DOI":"10.1136\/bmjopen-2014-005540","article-title":"Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)","volume":"4","author":"Quint","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2021.04.055_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jaip.2021.04.055_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40261-019-00792-7","article-title":"Addendum to: Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone\/corticosteroid therapy: population-based nested case-control study","volume":"39","author":"Morales","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaip.2021.04.055_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jaip.2021.04.055_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nm0796-814","article-title":"Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough","volume":"2","author":"Fox","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2021.04.055_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1365-2222.2003.01772.x","article-title":"Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients","volume":"33","author":"Currie","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.04.055_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/qjmed\/hcg071","article-title":"Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids","volume":"96","author":"Currie","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jaip.2021.04.055_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.122.1.146","article-title":"Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis","volume":"122","author":"Currie","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2021.04.055_bib25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1081-1206(10)62140-0","article-title":"Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis","volume":"90","author":"Currie","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2021.04.055_bib26","first-page":"76","article-title":"Captopril and bronchial reactivity","volume":"62","author":"Sala","year":"1986","journal-title":"Postgrad Med J"},{"issue":"suppl 10","key":"10.1016\/j.jaip.2021.04.055_bib27","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/00005344-198710100-00030","article-title":"Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma","volume":"10","author":"Riska","year":"1987","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00005344-199001000-00009","article-title":"Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma","volume":"15","author":"Riska","year":"1990","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1378\/chest.101.4.922","article-title":"Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma","volume":"101","author":"Kaufman","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2021.04.055_bib30","first-page":"335","article-title":"Bronchial responses to enalapril in asthmatic, hypertensive patients","volume":"12","author":"Mue","year":"1990","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2021.04.055_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2125.1987.tb03015.x","article-title":"The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects","volume":"23","author":"Dixon","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cpt.1018","article-title":"Rate of cough during treatment with angiotensin-converting enzyme inhibitors: a meta-analysis of randomized placebo-controlled trials","volume":"105","author":"Vukadinovi\u0107","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2021.04.055_bib33","doi-asserted-by":"crossref","first-page":"e2554","DOI":"10.1097\/MD.0000000000002554","article-title":"Comparison of the efficacy and safety of different ACEIs in patients with chronic heart failure: a PRISMA-compliant network meta-analysis","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2021.04.055_bib34","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: a UK population-based study","volume":"84","author":"Mahmoudpour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib35","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.ejim.2016.10.006","article-title":"Long delay to onset of ACEIs-induced cough: reason of difficult diagnosis in primary care?","volume":"37","author":"Humbert","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2021.04.055_bib36","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijcard.2014.07.108","article-title":"The incidence\u00a0and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease","volume":"176","author":"Brugts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaip.2021.04.055_bib37","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","author":"Mahmoudpour","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.jaip.2021.04.055_bib39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/fcp.12313","article-title":"The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case\/noncase study in VigiBase","volume":"31","author":"Alharbi","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib40","first-page":"e5624","article-title":"Demographic and clinical characteristics of patients presenting with angiotensin-converting enzyme inhibitors induced cough","volume":"11","author":"Jamshed","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2021.04.055_bib41","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11096-015-0159-3","article-title":"Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors","volume":"37","author":"Mahmoudpour","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jaip.2021.04.055_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2125.1998.00031.x","article-title":"Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients","volume":"46","author":"Speirs","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2019.07.010","article-title":"Scottish consensus statement on the role of FeNO in adult asthma","volume":"155","author":"Kuo","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2021.04.055_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.04.055_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","article-title":"Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study","volume":"15","author":"Morales","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jaip.2021.04.055_bib46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bcp.13006","article-title":"Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials","volume":"82","author":"Morales","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.04.055_bib47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/all.12629","article-title":"NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity","volume":"70","author":"Morales","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.04.055_bib48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1378\/chest.13-1235","article-title":"Adverse respiratory effect of acute \u03b2-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Morales","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2021.04.055_bib49","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2021.04.055_bib50","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821005614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821005614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:30:03Z","timestamp":1761975003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821005614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2213219821005614"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.04.055","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.04.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}